Establishment Labs Earnings Call Signals Profitable Growth

Establishment Labs Holdings ((ESTA)) has held its Q4 earnings call. Read on for the main highlights of the call.

Establishment Labs’ latest earnings call struck a decidedly upbeat tone as management highlighted strong 2025 growth, improving profitability metrics, and accelerating U.S. momentum. Executives balanced this optimism with a clear view of risks, including China volatility, reconstruction timing, and refinancing needs, but argued that operational tailwinds now meaningfully outweigh the headwinds.

Robust Revenue Growth in 2025

Establishment Labs posted Q4 2025 revenue of $64.6 million, a 45.2% year‑over‑year increase that underscored strong end‑of‑year demand. Full‑year revenue reached $211.1 million, rising 27.2% versus 2024 and signaling that the growth story is broad‑based rather than one‑quarter noise.

U.S. Motiva Adoption Becomes a Key Growth Engine

Motiva’s ramp in the U.S. is emerging as a central pillar of the story, with 2025 sales of $45.6 million and Q4 revenue of $17.3 million alone. Management said Motiva exited the year with roughly 20% share of the augmentation market and expects the U.S. to account for more than 30% of total sales in 2026.

Margin Expansion Strengthens the Financial Profile

Profitability is moving in the right direction as Q4 gross profit hit $45.5 million, representing a 70.5% gross margin and a 200 basis‑point improvement over the prior year quarter. For 2025 overall, gross margin improved by about 330 basis points versus 2024, giving the company more leverage to reinvest while narrowing losses.

Adjusted EBITDA Turns Positive and Trajectory Improves

The company delivered a notable profitability milestone with Q4 adjusted EBITDA of $5.5 million, reversing a $13.1 million loss in the same quarter of 2024. Management told investors they expect adjusted EBITDA to remain positive in every quarter of 2026 and forecast free cash flow turning positive that year.

Operating Loss Narrows and Liquidity Looks Solid

Q4 net loss from operations narrowed sharply to $3.9 million, a 79% improvement year‑on‑year that reflects both margin gains and cost discipline. The quarter ended with $75.6 million in cash, up $4.9 million, and management emphasized that they do not anticipate needing additional capital.

Ambitious 2026 Guidance Signals Confidence

For 2026, Establishment Labs guided revenue to a range of $264 million to $266 million, implying roughly 25% year‑over‑year growth from 2025’s base. The outlook also includes 200–300 basis points of further gross margin expansion and operating expenses between $195 million and $200 million, suggesting continued operating leverage.

Preserve and Mia Drive Minimally Invasive Momentum

The company’s minimally invasive offerings are gaining scale, with Preserve now available in 33 markets and used by more than 700 accounts. Mia surpassed its $8 million to $10 million 2025 target and more than doubled its account base, and management estimates global minimally invasive demand will exceed $30 million in 2026.

Commercial Traction and Account Expansion

Since a late‑2024 launch push, Establishment Labs has onboarded over 1,500 accounts around the globe, including a growing roster of high‑volume surgeons. To capitalize on this demand, the company plans to add up to 15 U.S. sales representatives in 2026 to deepen penetration and support rising patient interest.

China Weakness and Distributor Volatility

Not all markets are firing equally, with management calling out China as a particular challenge in the period that remains under active review. They also cautioned that distributor‑led markets can produce uneven quarter‑to‑quarter results due to order timing, adding some noise to reported sales.

Reconstruction Opportunity Shifts to 2027 and Beyond

The company submitted Motiva for a reconstruction indication in December 2025, but executives downplayed its near‑term revenue impact. They now view reconstruction as primarily a 2027 and beyond growth driver given regulatory timelines and the lag for hospital adoption and protocol changes.

Cash Use and Upcoming Credit Facility Maturity

While cash burn is moderating, management acknowledged the company will still use cash in 2026, though at less than half the 2025 level. The existing credit facility moves into its final year in April 2026, bringing refinancing strategy into focus even as the company approaches self‑funded cash generation.

Elevated Operating Expenses Reflect Investment Phase

Operating expenses are set to rise in 2026, with guidance of $195 million to $200 million and cash operating costs around $175 million to $180 million. Even so, management emphasized that spending growth will trail revenue growth, framing the elevated cost base as a necessary investment to support global expansion.

Seasonality and Uneven Quarterly Cadence

Investors were reminded that Establishment Labs’ results can be lumpy, with first quarters typically softer and some costs weighted to the back half of the year. This seasonality and spending pattern could create non‑linear quarter‑to‑quarter performance even if the full‑year trajectory remains intact.

Execution Risks in a Rapid Commercial Ramp

The company’s growth plan depends heavily on effective execution as it accelerates U.S. expansion and adds sales reps. Management noted that slower‑than‑expected rep productivity or weaker surgeon and patient adoption could pressure the ramp, making field execution a key watch point.

Management Transition Adds a Variable

A leadership reshuffle saw the current finance chief move into a global strategy role while Cassandra Harris steps in as the new CFO. While framed as a positive evolution, any C‑suite transition introduces integration and execution risk at a time when the company is scaling quickly.

Forward Guidance Points to Profitable Growth

Looking ahead, management projects 2026 revenue of $264 million to $266 million, driven by high‑growth U.S. sales exceeding 30% of the mix and single‑digit gains outside the U.S. They also expect margin expansion, positive adjusted EBITDA every quarter, sharply reduced cash burn, and a path to cash‑flow profitability without relying on new equity.

Establishment Labs’ earnings call painted a picture of a company shifting from early‑stage growth to a more balanced expansion and profitability phase. With strong U.S. momentum, improving margins, and rising minimally invasive demand, the story remains compelling, though investors will need to track China trends, execution on the U.S. ramp, and upcoming refinancing steps closely.